Adherence to medications and total mortality within the disease subgroups and by sections of follow-up duration
| HR | 95% CI | P values | |
| Analyses within patient subgroups* | |||
| NSTEMI | 5.77 | 1.61 to 20.63 | 0.007 |
| STEMI | 11.37 | 3.46 to 37.36 | <0.001 |
| UA | 49.6 | 5.59 to 440.39 | <0.001 |
| SCAD | 12.31 | 3.37 to 44.97 | <0.001 |
| Analyses in all patients† | |||
| Total follow-up | 10.28 | 5.51 to 19.18 | <0.001 |
| Follow-up only postdischarge | 9.74 | 5.04 to 18.85 | <0.001 |
*Models were adjusted for age, sex, hypertension, hyperglycaemia, Killip class, eGFR, PCI/CABG, thrombolysis/anticoagulants, onset to admission, hospital stay, and rehospitalisation for MI, stroke or heart failure.
†Models were adjusted for age, sex, hypertension, hyperglycaemia, Killip class, cardiac biomarkers, ST-segment elevation, eGFR, PCI/CABG, thrombolysis/anticoagulants, onset to admission, hospital stay, rehospitalisation for MI, stroke or heart failure, socioeconomic status, and residence distance from the hospital.
CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; SCAD, stable coronary artery disease; STEMI, ST-elevation myocardial infarction; UA, unstable angina.